8 October 2021 in Pediatric Hematology/Oncology and Immunopathology
Tumor thrombosis of the central venous system in children with embryonal tumors is a rare complication, requiring a comprehensive treatment approach, with chemotherapy and the intervention of a multidisciplinary team of oncologists and cardiac surgeons. The article describes the medical history of a 9-month-old patient with bilateral nephroblastoma and tumor thrombosis of inferior vena cava and right atrium, as well as provides a brief review of the literature. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.
1 January 2022 in Journal of Venous Disorders
Опухолевый тромбоз нижней полой вены и правого предсердия считают редким осложнением в детской солидной онкологии. Лечение таких пациентов сопряжено с высокими рисками осложнений и неблагоприятного исхода, что требует мультидисциплинарного подхода и использования высокотехнологичного оборудования на всех этапах комбинированного или комплексного лечения. На сегодняшний день не решен ряд вопросов, касающихся деталей оперативного вмешательства, подготовки пациентов к хирургическому лечению и наблюдения в послеоперационном периоде. В статье описан случай успешного хирургического лечения пациентки с нефробластомой левой почки и опухолевым тромбозом нижней полой вены и правого предсердия, а также представлен обзор актуальной литературы.
9 December 2020 in ChemChemTech
В рамках государственной программы импортозамещения для разработки отечественной противоизносной присадки к топливам для реактивных двигателей на первом этапе были проанализированы физико-химические характеристики допущенных к применению зарубежных противоизносных присадок ДНК, HITEC 580 и Unicor J. В ходе этого анализа выявлено, что при производстве присадок HITEC 580 и Unicor J для улучшения их потребительских свойств (низкотемпературных характеристик) используют растворители. На втором этапе исследования методом хромато-масс-спектрометрии изучен и исследован состав применяемых в настоящее время присадок HITEC 580 и Unicor J. Показано, что в их составе используется один и тот же активный компонент – димеры ненасыщенных жирных кислот С18, а именно смесь димеров линоленовой, линолевой и олеиновой кислот, среди которых преобладает димер образованный из линолевой и олеиновой кислот. В ходе анализа используемых в составе присадок растворителей показано, что при производстве присадки Unicor J используют ароматический растворитель, содержащий 92% моноароматических соединений, преимущественно ряда С10, что, вероятно, является продуктом риформинга бензинов, а присадки HITEC 580 – алифатический растворитель, содержащий преимущественно н-алканы (41%). Из представленных результатов исследования следует, что при разработке рецептуры отечественной противоизносной присадки в качестве активного компонента необходимо выбирать соединения, содержащие 1 или 2 карбоксильные группы, а в качестве растворителя либо ароматический, либо алифатический, в зависимости от стоимости и наличия на отечественном рынке. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23 July 2009 in Interactive CardioVascular and Thoracic Surgery
The current study is of special interest for those specialists who face severe heart failure after open-heart surgery. Extracorporeal membrane oxygenation (ECMO) is an effective procedure in the treatment of severe post-surgical heart failure resistant to pharmacotherapy. When correctly used as it is indicated the success rate may reach 58% [1]. According to the literature, data survival rate may vary from 29% [2] to 65% [3]. The results of ECMO application may differ depending on patients' age, initial status, type of surgical procedure, type of postoperative complications [2–5]. Certainly, it is important to use ECMO also as a bridge to heart transplantation. Meantime the mortality is still high (42%) because of the severity of initial status. Other high-risk factors of mortality are multiorgan failure, generalized infection, coagulation system disorders. Patients suffering from renal failure and demanding hemodialysis are in the high-risk group as well. Combining ECMO with other mechanical circulatory support systems (e.g. IABP) and preventive treatment of possible complications may improve the clinical results. Despite the little experience shown in the current study we congratulate the authors on their results.
29 June 2026 in Complex Issues of Cardiovascular Diseases
Highlights This study by the A.N. Bakulev NMRC of Cardiovascular Surgery reports for the first time in Russia on domestic clinical experience with transcatheter pulmonary valve implantation. Against the backdrop of the widespread adoption of this minimally invasive alternative to open surgery, the study provides a detailed analysis of the immediate results, efficacy, and safety of the technique at the A.N. Bakulev NMRC of Cardiovascular Surgery, which has performed the largest number of implants in the country.
Aim
.
Evaluation of the safety and efficacy of transcatheter pulmonary valve implantation in the 30-day postoperative period.
Methods
.
A prospective single-center study included 55 patients aged 9 to 32 years (mean age 14.7 ± 3.36 years, male – 43 (78.2%)), operated on at the A.N. Bakulev National Medical Research Center of Cardiovascular Surgery in the period from June 2023 to November 2025 (1 patient – in 2008, assessed retrospectively). The most common initial diagnosis was tetralogy of Fallot (n = 29 (52.72%)). In 32 patients (58.18%), valve implantation was performed in the native right ventricular outflow tract (RVOT), 17 (30.91%) – in a conduit, 6 (10.91%) – in an allograft. In 9 cases (16.36%), implantation was performed into a stented conduit, in 3 cases (5.45%) – into a previously installed pulmonary valve prosthesis. The predominant pathophysiological mechanism was a combination of stenosis and regurgitation (56.37% (n = 31)); isolated pulmonary regurgitation was detected in 20 patients (36.36%), and isolated pulmonary valve stenosis was found in 4 patients (7.27%). The median lumen area in the implantation zone was 482.3 (279.1; 601.4) mm 2 .
Results
.
Valves were implanted in all 55 (100%) patients. The following stent valves were implanted: 38 (69.1%) Myval, 13 (23.64%) Pulsta, 2 each (3.63%) VenusP-Valve and Melody. The median stent-valve diameters were 27.5 (23; 32) mm. The median intervention time was 85 (65; 135) min. The invasive RVOT systolic pressure gradient decreased from 15 (10; 29) to 9 (4; 15) mmHg after the surgery, and the noninvasive peak gradient decreased from 40 (26; 60) to 14 (8; 20) mmHg. Pulmonary regurgitation was eliminated or became minimal in 100% of patients. Technical success of the procedure was achieved in 94.5% (n = 52) of cases, and clinical success was achieved in 96.36% (n = 53). 3 (5.45%) complications occurred, 1 of which (1.82%) was intraoperative and required surgical stent removal (prestenting). There were no cases of valve displacement or dysfunction during the follow-up period, and the mortality rate was 0%.
Conclusion
.
Transcatheter pulmonary valve implantation is an effective and safe alternative to repeated cardiac surgery in the treatment of patients who have underwent multi-stage surgical correction of congenital heart disease.